Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma.

× No keyword cloud information.

12 in total

Review 1. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.

Authors: T Boon; P Coulie; M Marchand; P Weynants; T Wölfel; V Brichard
Journal: Important Adv Oncol Date: 1994

Review 2. Therapy for cutaneous melanoma: an update.

Authors: V C Ho; A J Sober
Journal: J Am Acad Dermatol Date: 1990-02 Impact factor: 11.527

3. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

Authors: B Gansbacher; R Bannerji; B Daniels; K Zier; K Cronin; E Gilboa
Journal: Cancer Res Date: 1990-12-15 Impact factor: 12.701

4. Retroviral interleukin 4 gene transfer into an interleukin 4-dependent cell line results in autocrine growth but not in tumorigenicity.

Authors: T Blankenstein; W Q Li; W Müller; T Diamantstein
Journal: Eur J Immunol Date: 1990-04 Impact factor: 5.532

5. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors: G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal: Proc Natl Acad Sci U S A Date: 1993-04-15 Impact factor: 11.205

6. Determination of granulocyte/macrophage-colony-stimulating factor secretion by human melanoma cells and its effects on human melanoma cell proliferation.

Authors: D Schadendorf; M Worm; B M Czarnetzki
Journal: J Cancer Res Clin Oncol Date: 1993 Impact factor: 4.553

7. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.

Authors: D Schadendorf; M Böhm; P Möller; T Grünewald; B M Czarnetzki
Journal: J Invest Dermatol Date: 1994-06 Impact factor: 8.551

2. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.

Authors: P Möller; Y Sun; T Dorbic; S Alijagic; A Makki; K Jurgovsky; M Schroff; B M Henz; B Wittig; D Schadendorf
Journal: Br J Cancer Date: 1998-06 Impact factor: 7.640

2 in total

Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma.

Review 1. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.

Review 2. Therapy for cutaneous melanoma: an update.

3. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

4. Retroviral interleukin 4 gene transfer into an interleukin 4-dependent cell line results in autocrine growth but not in tumorigenicity.

5. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

6. Determination of granulocyte/macrophage-colony-stimulating factor secretion by human melanoma cells and its effects on human melanoma cell proliferation.

7. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.

8. Interleukin 7 induces CD4+ T cell-dependent tumor rejection.

9. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.

10. Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells.

1. Immunotherapy of mice with an irradiated melanoma vaccine coupled with interleukin-12.

2. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.